文献速递消化道肿瘤与早癌

多价酪氨酸激酶抑制通过肿瘤内在IFN-γ信号限制上皮-间质转化促进T细胞募集至免疫荒漠型胃癌

Multivalent tyrosine kinase inhibition promotes T cell recruitment to immune-desert gastric cancers by restricting epithelial-mesenchymal transition via tumour-intrinsic IFN-γ signalling.
PubMed 文献 · Gut · 2023-07-04

研究基于免疫细胞浸润将人胃癌分为免疫炎症型、排斥型和荒漠型,发现荒漠型胃癌富集上皮-间质转化信号且对CTLA4阻断耐药。多靶点RTK抑制剂多韦替尼抑制EMT编程、激活肿瘤内在SNAI1/2-IFN-γ信号轴,将免疫荒漠型肿瘤转化为炎症型并增敏CTLA4阻断。

要点

  • 免疫荒漠型和排斥型胃癌较免疫炎症型对免疫检查点阻断耐药。
  • 多韦替尼抑制EMT并激活SNAI1/2-IFN-γ轴,使冷肿瘤对CTLA4阻断增敏。
  • 免疫荒漠型胃癌中鉴定出一组RTK为潜在可成药靶点。

核心结论

  • 研究发现免疫荒漠型胃癌的潜在可成药靶点,多韦替尼通过限制EMT和募集T细胞使荒漠型免疫冷胃癌对CTLA4阻断增敏。

研究设计与样本

  • 开发算法将人胃癌重新分类为免疫炎症型、排斥型和荒漠型,并结合生物信息学、人和小鼠胃癌细胞系、同基因小鼠胃肿瘤模型及CTLA4阻断进行研究。

主要发现

  • 算法在公共数据库中对人胃癌亚型重新分层,显示免疫荒漠型和排斥型肿瘤较免疫炎症型胃癌对免疫检查点阻断耐药。
  • 免疫荒漠型胃癌中EMT信号高度富集,同基因小鼠中呈间质样而非上皮样特性的肿瘤T细胞排斥且对CTLA4阻断耐药。
  • 多韦替尼在间质样免疫荒漠同基因胃癌模型中显著抑制EMT编程,激活肿瘤内在SNAI1/2-IFN-γ信号轴,将免疫荒漠型肿瘤转化为免疫炎症型并增敏CTLA4阻断。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Gastric cancer (GC) ranks fifth in incidence and fourth for mortality worldwide. The response to immune checkpoint blockade (ICB) therapy in GC is heterogeneous due to tumour-intrinsic and acquired immunotherapy resistance. We developed an immunophenotype-based subtyping of human GC based on immune cells infiltration to develop a novel treatment option. DESIGN: A algorithm was developed to reclassify GC into immune inflamed, excluded and desert subtypes. Bioinformatics, human and mouse GC cell lines, syngeneic murine gastric tumour model, and CTLA4 blockade were used to investigate the immunotherapeutic effects by restricting receptor tyrosine kinase (RTK) signalling in immune desert (ICB-resistant) type GC. RESULTS: Our algorithm restratified subtypes of human GC in public databases and showed that immune desert-type and excluded-type tumours are ICB-resistant compared with immune-inflamed GC. Moreover, epithelial-mesenchymal transition (EMT) signalling was highly enriched in immune desert-type GC, and syngeneic murine tumours exhibiting mesenchymal-like, compared with epithelial-like, properties are T cell-excluded and resistant to CTLA4 blockade. Our analysis further identified a panel of RTKs as potential druggable targets in the immune desert-type GC. Dovitinib, an inhibitor of multiple RTKs, strikingly repressed EMT programming in mesenchymal-like immune desert syngeneic GC models. Dovitinib activated the tumour-intrinsic SNAI1/2-IFN-γ signalling axis and impeded the EMT programme, converting immune desert-type tumours to immune inflamed-type tumours, sensitising these mesenchymal-like 'cold' tumours to CTLA4 blockade. CONCLUSION: Our findings identified potential druggable targets relevant to patient groups, especially for refractory immune desert-type/ 'cold' GC. Dovitinib, an RTK inhibitor, sensitised desert-type immune-cold GC to CTLA4 blockade by restricting EMT and recruiting T cells.

来源:Gut,查看原文。版权归原作者所有。

引用

  1. Cao LL, Lu H, Soutto M, et al. Multivalent tyrosine kinase inhibition promotes T cell recruitment to immune-desert gastric cancers by restricting epithelial-mesenchymal transition via tumour-intrinsic IFN-γ signalling. Gut. 2023. PMID: 37402563. doi:10.1136/gutjnl-2022-329134

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。